SNY had Hatch-Waxman exclusivity for Lovenox in the STEMI indication until 5/16/10 (#msg-43243987), so posters on this board had entertained the possibility that Bill Marth was referring to a label carve-out for this indication.
Now, however, I’m inclined to agree with dewophile that Bill Marth’s talk about Teva’s being in “labeling discussions” with the FDA one year ago was simply BS.
Market Data 
Markets 
AI
